TECKRO
29.9.2021 15:06:05 CEST | Business Wire | Press release
Teckro, the creator of the only clinical trials platform that facilitates collaboration and real-time decision-making between and among stakeholders, announces new product capabilities to accelerate site adoption of modern trial practices, making communication even easier at the point of care. A next-generation mobile app gives investigators and site staff answers in fewer clicks, while platform enhancements will result in new studies operational on Teckro in half the time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005472/en/
Toward its vision of engaging every physician in clinical research, Teckro also unveils its “Teckro Powered” site program to establish a community of research sites ready to advance the industry and help shape future product requirements. Today, more than 23,000 research sites around the world rely on the Teckro platform for clinical trials in all therapeutic areas.
“With a critical mass of sites using Teckro, we deepen our commitment to a simple, site-driven experience that allows physicians to easily engage in research without compromising time caring for patients,” says Teckro CEO Gary Hughes. “Sponsors can ease the complexity of clinical trials with a frictionless way to communicate with sites, including when investigators can receive direct guidance from study experts at the point of care.”
First-Of-Its-Kind Site Program: Teckro Powered
“Teckro Powered” is a novel program open to any research site. The program includes a dedicated sandbox to preview Teckro capabilities and input into future requirements. In addition with the program, sites and site networks can:
- Build a technology-ready brand. Teckro Powered sites are technically savvy. Designated with a program badge on their websites and social media platforms, sites can use this to differentiate themselves and build their reputations as “sites of choice” for sponsors.
- Expand physician participation in research. Behind the Teckro Powered program is a community of research sites to open a new way to collaborate and advance the industry. With the strength of a Teckro Powered community, the goal is to encourage more physicians to participate in clinical trials, reaching broader, diverse patient populations.
- Limit impact of staff turnover. Teckro Powered is a way for sites to mitigate disruption from staff turnover. With study resources conveniently hosted in Teckro and accessible from a smartphone, sites can simplify new study member onboarding. A central source for content, communication and collaboration reduces the time to train new staff over the course of a trial.
“The Teckro Powered program fills a gap in the industry,” says Director of Site Strategy Silvina Baudino. “Working with sites for almost 20 years, I know how challenging clinical research can be. Teckro is dedicated to the site experience, which you see in both the new product capabilities and the investment in the Teckro Powered program. We are creating a way for sites to differentiate themselves and participate in a community of research sites.”
Maximizing Sponsor-Site Collaboration
Teckro’s latest platform enhancements go toward solving gaps in communication and easing the burden on site staff. A hub for study content and communication, the new Teckro capabilities include:
- Next-generation mobile application. The streamlined app provides a simple, mobile-first user experience to support point of care decisions. Based on deep user research, the new mobile application is optimally designed for clinical trial answers in just a couple of clicks. The new Teckro mobile app is now available in the app stores for Apple and Android smartphones.
- Diverse experts on demand . Teckro is expanding its communication to support more granular groups of experts for different types of site queries. Real-time guidance from those best suited to provide answers eliminates the need for a “switchboard” or for study monitors to operate as a go-between. The feature will be available in the fourth quarter.
- Increased speed and scale. Underlying platform improvements mean new studies can be added in half the time. This allows sponsors to standardize on Teckro as a resource for their sites to access current study content and communications across trials.
Meet Teckro at the Global Site Solution Summit
Teckro is a sponsor at the upcoming Global Site Solution Summit (October 1-3). Visit us at Booth 716 to see a demo and talk with our experts. You can also request a meeting with Silvina Baudino (Teckro director of site strategy) or Malia Lewin (Teckro global head of strategy) by completing the form on our event page
. Silvina will also participate as a panelist in the breakout session “It's Not You, It's Me: How to Manage Long-Term Partnerships” on both October 2 at 1:30 p.m. and October 3 at 9 a.m.
About Teckro
Recognized as one of the fastest growing clinical trial start-ups, Teckro transforms the study protocol into a hub of communication and collaboration. It’s a digital platform that connects all study stakeholders with the knowledge they need, when they need it. Thousands of investigators and more than 23,000 sites around the world rely on Teckro to execute clinical trials from biopharma sponsors, including 12 out of the Top 20 pharma companies. Teckro supports all therapeutic areas, all phases, and any trial format ranging from traditional in-clinic, decentralized clinical trials, or a hybrid approach.
More Information
- Visit teckro.com
- Connect with Teckro on LinkedIn
- Follow @teckroofficial on Twitter and Instagram
- Like Teckro on Facebook
- Subscribe to the Teckro YouTube channel
- Named as one of Linkedin’s official top ten Irish startups 2021
- Featured on Sifted’s Irish startups to watch list 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20210929005472/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GenBio AI Builds First World Model of the Human Cell18.8.2026 15:00:00 CEST | Press release
First-of-its-kind system simulates human cell behavior across the full biological hierarchy, from DNA and RNA through protein to the whole-cell level GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions. Today, the company introduced AIDO Cell, its virtual cell world model — the first system capable of simulating a human cell, both in its natural state and in response to drugs and other interventions, across its full biological hierarchy, from DNA and RNA through protein to the whole-cell level. A Key First in Biological and Medical Sciences: Full-hierarchy virtual cell simulation has been widely identified as a key milestone in computational biology. Compared to the previous efforts by
Xsolla Partner Network Expands Verified Creator Partnerships and Unifies Campaign Management Ahead of gamescom 202618.8.2026 15:00:00 CEST | Press release
Developers Gain Vetted Creator Partnerships And A Single Campaign Workflow, Managed From The Publisher Account They Already Use Xsolla, a global video game commerce company, today announced an expansion of the Xsolla Partner Network ahead of gamescom 2026 in Cologne, giving game developers a simpler, more reliable way to grow their games through creators. The creator platform now lives within Xsolla Publisher Account, where developers already run their business, with verified creator onboarding and a redesigned and unified campaign workflow. Flat-fee campaigns, a new guaranteed payment option alongside revenue share, and data-driven creator recommendations are coming soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818140062/en/ Graphic: Xsolla Xsolla Partner Network gives developers one place to launch, manage, track, and report on creator campaigns while Xsolla handles payments, payouts, taxes, and compliance.Verifi
KOCCA to Showcase 13 Korean Game Companies at ‘Gamescom 2026’ with PC, Mobile, and VR Lineups18.8.2026 14:48:00 CEST | Press release
- Featuring a diverse lineup of roguelike deckbuilders, AI-powered rhythm education, and cooperative horror games - Ranging from new titles based on the popular animated IP ‘LARVA’ to real-time K-POP dance coaching content - Hands-on experience available August 26–28 at the Korea Joint Pavilion B2B Hall, Koelnmesse, Booth Hall 3.2 C-050g–D051g The Korea Creative Content Agency (KOCCA) announced that 13 Korean game companies will gather under one roof at Gamescom 2026, Europe’s largest game show, held in Cologne, Germany, from August 26 to 28 (B2B, 09:00~20:00). Located in Booth Hall 3.2 C-050g–D051g, the Korea Joint Pavilion offers visitors hands-on experiences with an expansive lineup of titles, ranging from PC and mobile games to VR-powered titles across diverse genres. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818271881/en/ KOCCA will bring 13 Korean game companies to Gamescom 2026 in Cologne, Germany (Image: KOCC
SLB to Support Offshore Production Restoration for Brunei Shell Petroleum18.8.2026 14:06:00 CEST | Press release
Integrated execution model combines multiple disciplines to improve recovery from mature offshore assets Global energy technology company SLB (NYSE: SLB) today announced it has been awarded a contract by Brunei Shell Petroleum (BSP) to support production restoration from shut-in wells across multiple offshore fields. The contract scope spans subsurface evaluation, well candidate selection, engineering and offshore execution. Project management, intervention services, monitoring, metering and marine logistics are integrated within a single coordinated execution model designed to support efficient production restoration. “Building on our long collaboration in the region, this contract reflects a shared commitment to maximizing value from existing offshore resources,” said Gokhan Yarim, senior vice president of Integration, SLB. “Together with BSP, we are combining SLB’s production expertise and integrated execution capabilities to help restore production from shut-in wells, increase reco
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries18.8.2026 12:00:00 CEST | Press release
Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028 BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively. Building on a collaboration launched in 2023, the renewed partnership reflects the organizations’ shared commitment to improving access to innovative cancer treatments in underserved communities. To date, the partnership has enabled access to BRUKINSA for more than 300 patients with CLL across Armenia, Ethiopia, and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
